Nonmelanoma Skin Cancer – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of nonmelanoma skin cancer comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the incidence and prevalence of basal and squamous cell carcinoma for each country, as well as annualized case counts projected to the national population.
In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in the first line of therapy.
Clarivate Epidemiology’s basal and squamous cell carcinoma forecast will answer the following question:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of basal and squamous cell carcinoma over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Clarivate Epidemiology provides at least 10 years of forecast data for the following:
- Total number of cases of basal and squamous cell carcinoma for each forecast year.
- Diagnosed incident cases of basal and squamous cell carcinoma.
- Diagnosed incident cases of basal and squamous cell carcinoma (nonmetastatic and metastatic) by stage.
- Recurrent incident cases of basal and squamous cell carcinoma.
- Diagnosed prevalent cases of basal and squamous cell carcinoma.
- First-line drug-treatable cases of basal and squamous cell carcinoma.
- … and more (details available on request).
Note: Coverage may vary by country.
Table of contents
- Nonmelanoma Skin Cancer - Epidemiology - Mature Markets
- Epidemiology data
- Methods
- Literature review studies included in/excluded from the analyses of basal and squamous cell carcinoma
- Diagnosed incident cases of basal cell carcinoma
- Diagnosed incident cases of squamous cell carcinoma
- Stage distribution of basal cell carcinoma
- Stage distribution of squamous cell carcinoma
- Recurrent incident cases of basal cell carcinoma
- Recurrent incident cases of squamous cell carcinoma
- Drug-treatable populations of basal cell carcinoma
- Drug-treatable populations of squamous cell carcinoma
- Diagnosed prevalent cases of basal cell carcinoma
- Diagnosed prevalent cases of squamous cell carcinoma
- Risk / protective factors applied to disease forecast models
- Reference materials
- Bibliography
- Glossary
- Abbreviation table
Shilpa Thakur, M.P.H., is an epidemiologist at Clarivate. Previously, she monitored HIV sentinel surveillance in Himachal Pradesh. She has also studied the patterns of antimicrobial resistance in India. She received her M.P.H. from the Postgraduate Institute of Medical Education and Research with a specialization in epidemiology and biostatistics.
Swarali Tadwalkar, M.P.H., is a principal epidemiologist at Clarivate. Previously, she was involved in primary and secondary healthcare research, including projects in digital health, health policy and management, and health economics and outcomes research (HEOR). Ms. Tadwalkar also coordinated various nongovernmental public health projects focusing on access to treatment for hepatitis and human papilloma virus. She received her M.P.H. from the University of South Florida in Tampa.